scholarly journals The Hematopoietic Cell Transplantation-Specific Comorbidity Index Fails to Predict Outcomes in High-Risk AML Patients Undergoing Allogeneic Transplantation—Investigation of Potential Limitations of the Index

2011 ◽  
Vol 17 (12) ◽  
pp. 1822-1832 ◽  
Author(s):  
Nicole Birninger ◽  
Martin Bornhäuser ◽  
Markus Schaich ◽  
Gerhard Ehninger ◽  
Johannes Schetelig
Keyword(s):  
High Risk ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Allogeneic Transplantation ◽  
Hematopoietic Cell ◽  
Comorbidity Index

scholarly journals ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

2010 ◽  
Vol 2 (2) ◽  
pp. e2010015 ◽  
Author(s):  
Mohamed L. Sorror ◽  
Rainer F. Storb
Keyword(s):  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Medical Condition ◽  
Laboratory Data ◽  
Young Patients ◽  
Allogeneic Transplantation ◽  
Hematopoietic Cell ◽  
High Dose ◽  
Conditioning Regimens ◽  
Comorbidity Index

Allogeneic conventional hematopoietic cell transplantation (HCT) following high-dose, myeloablative conditioning regimens has been used since the 1970’s as potentially curative treatment for patients with malignant, hematological disorders. The toxicities of conditioning regimens have limited conventional HCT to relatively young patients in otherwise good medical condition. With the development of less toxic nonmyeloablative regimens and improvements in supportive care, increasing numbers of older and medically infirm patients have been treated by allogeneic HCT. Until recently, there has been almost no effort to evaluate the prevalence of comorbidities among HCT recipients and their impact on outcomes. We first evaluated the Charlson Comorbidity Index (CCI) developed for patients with solid malignancies, for this purpose. While useful, it lacked sensitivity and specificity for the HCT setting. We next introduced the HCT-specific comorbidity index (HCT-CI) which was based on objective laboratory data to better define comorbidities. Here, we describe this development and illustrate the usefulness of the HCT-CI in predicting HCT outcomes in patients with myeloid and lymphoid malignancies undergoing allogeneic transplantation 

Sign in / Sign up

Export Citation Format

Share Document